NCT01241643终止2 期
A Multicenter, Open-labeled, Controlled, Randomized Study of Recombinant Interleukin-7 (CYT107) Treatment to Restore and Maintain CD4 T-lymphocyte Counts Above 500 Cells/µL in HIV-infected Patients With CD4 Counts Remaining Between 101-350 Cells/µL After at Least 2 Years of HAART and Plasma HIV RNA < 50 Copies/mL for 18 Months.
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- Cytheris SA
- 入组人数
- 92
- 试验地点
- 3
- 主要终点
- To study the biological activity and safety of repeated cycles of CYT107 at 20 µg/kg/week over 2 weeks, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months.
研究概览
简要总结
This is a Phase II multicenter, open-labeled, controlled, randomized study assessing weekly doses of Interleukin-7 (CYT107)
详细描述
The aim of the study is to assess repeated cycles of 3 weekly injections of CYT107 in patients immune non-responders infected with HIV.
Eighty patients will be recruited to study the biological activity and safety of repeated cycles of CYT107 at 20 µg/kg/week over 2 weeks, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months. The entire study will cover a period of 24 months.
During the study visits the following may be done:
- medical history, physical examination, blood test every visit
- EKG
- chest X-Ray
- liver/spleen ultrasound
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •HIV-1 infection as documented by any licensed ELISA (Enzyme-Linked Immunosorbent Assay) test kit and confirmed either by Western Blot or a 2nd test using a different method at any time prior to study entry
- •On HAART (Highly active anti-retroviral therapy) for at least 24 months, on stable regimen for at least 6 months prior to study entry. HAART is defined as a combination of two (2) classes dose regimen of approved ARV (antiretroviral)
- •CD4+ cell counts ≥ 101 and < 350 cells/µL measured on at least two (2) measurements (including the screening value) within the previous 12 months prior to study entry Note: a single isolated value of CD4+ ≥ 350 during this period (12 months prior to study entry) will be allowed to participate if the previous and subsequent CD4+ count is in the range of ≥ 101 and < 350 cells/µL
- •Plasma HIV RNA < 50 copies/mL since at least 18 months with at least two (2) measurements (including the screening value) within the previous 6 months prior study entry Note: patients with single blip of detectable viremia during this period (6 months prior to study entry) will be allowed to participate if the prior and subsequent plasma HIV RNA levels are < 50 copies/mL
- •Adequate bone marrow, hepatic and renal function as follows:
- •Hemoglobin ≥ 10 g/dl
- •Neutrophils ≥ 1,000/µL
- •Platelets ≥ 100,000/µL
- •AST, ALT, or Alk. Phosph. ≤ 2.5 x ULN
- •Total Bilirubin ≤ 1.5 x ULN (or ≤ 5 x ULN if the patient is treated by atazanavir or by indinavir, and if the increase is due to unconjugated bilirubin and if ALT and AST are normal)
- •Lipase ≤ 2 x ULN
- •PT/PTT ≤ 1.5 x ULN
- •Estimated glomerular filtration ≥ 60 ml/min (according to MDRD formula)
- •Normal blood Thyroid-Stimulating Hormone (TSH)
- •Ability to understand and sign informed consent
排除标准
- •AIDS-defining illness (category C) diagnosed within the last 12 months prior to study entry
- •History of HIV related encephalopathy
- •Active opportunistic infection including active tuberculosis
- •Previous treatment with IL-2 or IL-7 at any time prior to study entry
- •Any planned or probable modification of the anti-retroviral treatment during the first year or the first two cycles of CYT107 Note: in case of product shortage and in absence of viral mutation suspicion or viral blip, a modification of ARV will not be an exclusion criterion
- •Poor compliance on HAART or any other chronic treatment that in the opinion of the investigator will interfere with protocol participation
- •Previous treatment with immuno-modulatory agents such as, systemic corticosteroids, growth factors, immunosuppressive drugs, HIV vaccine, or anti-cancer treatment or hydroxyurea within 3 months prior to study entry
- •Any history of malignancy (except basal carcinoma of the skin) including any hematologic malignancy or AIDS defining malignancy, such as lymphoproliferative disorder or Kaposi's sarcoma Note: Patients with Kaposi's sarcoma limited to the skin that had disappeared while on HAART therapy, and without requiring any other systemic therapy 1 year prior to study entry, will be eligible.
- •Any history of severe auto-immune disease requiring systemic treatment or hospitalization, or any active auto-immune disease requiring treatment (including multiple sclerosis)
- •History of splenectomy
- •Any hematologic disease associated with hypersplenism, such as thalassemia, hereditary spherocytosis, Gaucher's Disease, and autoimmune hemolytic anemia
- •Chronic hepatitis B or C
- •HIV-2, HTLV-1 or HTLV-2 seropositivity
- •Cirrhosis of any origin, and alcoholic or non alcoholic steato-hepatitis, either proven histologically or suspected
- •Hypertension with a resting systolic blood pressure > 140 or a resting diastolic blood pressure > 90 mm despite adequate antihypertensive treatment
- •Any cardiac, pulmonary, thyroid, renal, hepatic, gastrointestinal, neurological (central or peripheral) disease requiring therapy and considered as significant by the investigator or a severe disorder of hemostasis
- •Any serious illness requiring systemic treatment and/or hospitalization until the patient either completes therapy or is clinically stable on therapy, in the opinion of the principal investigator, for at least 30 days prior to study entry
- •Pregnant or lactating women. Women of childbearing potential must have a negative serum or urine pregnancy test at study entry
- •Refusal or inability to practice contraception regardless of the gender of the patient
研究组 & 干预措施
CYT107
Experimental
repeated cycles of CYT107 at 20 µg/kg/week over 2 weeks, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months
干预措施: CYT107 (Drug)
结局指标
主要结局
To study the biological activity and safety of repeated cycles of CYT107 at 20 µg/kg/week over 2 weeks, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months.
时间窗: 24 months
次要结局
- To characterize CYT107 Pharmacokinetics (PK) / Pharmacodynamics (PD)(24 months)
- To characterize the key immuno-pharmacological effects(24 months)
- To assess CYT107 effect on HIV-induced chronic systemic immune hyper-activation and its consequences(24 months)
研究者
研究点 (3)
Loading locations...
相似试验
招募中
2 期
Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab in Advanced Hepatocellular CarcinomaHepatocellular CarcinomaNCT06558227Suzhou Zelgen Biopharmaceuticals Co.,Ltd90
终止
2 期
A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)Non-Small Cell Lung CancerNCT00434226Genentech, Inc.56
Unknown
2 期
Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer PatientsTriple Negative Breast CancerNCT04502680The First Affiliated Hospital with Nanjing Medical University100
撤回
2 期
A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid LeukemiaAcute Myeloid LeukemiaNCT04100330AVEO Pharmaceuticals, Inc.
Unknown
2 期
Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOCFallopian Tube CancerPeritoneal CancerEpithelial Ovarian CancerNCT04983550CSPC ZhongQi Pharmaceutical Technology Co., Ltd.126